arrow
C

Chiara Sacco

Istituto Superiore di Sanità
H指数:21
被引数:2,318

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Unmeasured confounding and misclassification in studies estimating vaccine effectiveness against hospitalisation and death using electronic health records (EHRs): an evaluation of a multi-country European retrospective cohort study

未测量混杂和错分偏倚在利用电子健康记录(EHRs)评估疫苗对住院和死亡的保护效果研究中的影响:一项多国欧洲回顾性队列研究的评估

2025-12-170
OAAI
Effectiveness of the 2023 Autumn XBB.1.5 COVID-19 Booster During Summer 2024 in the EU/EEA: A VEBIS Electronic Health Record Network Study

2023年秋季XBB.1.5 COVID-19加强针在2024年夏季于欧盟/欧洲经济区内的有效性:一项VEBIS电子健康记录网络研究

2025-11-280
OAAI
Temporal trend and individual and hospital characteristics associated to vancomycin-resistant Enterococcus faecium bloodstream infections: a retrospective analysis from the national surveillance system, Italy 2015–2023

万古霉素耐药粪肠球菌血流感染的时序趋势及其与个体和医院特征的关系:一项来自意大利国家监测系统2015-2023年的回顾性分析

2025-10-150
OAAI
Effectiveness of JN.1 monovalent COVID-19 vaccination in EU/EEA countries between October 2024 and January 2025: a VEBIS electronic health record network study

JN.1单价COVID-19疫苗接种在欧盟/欧洲经济区国家(2024年10月至2025年1月)的有效性:一项VEBIS电子健康记录网络研究

Vaccine
IF3.5
2025-09-190
PRE
Detection of Dengue virus RNA in Wastewater during a Local Epidemic in Central Italy (August–October 2024)

在意大利中部地方性登革热疫情期间(2024年8月至10月)废水中登革病毒RNA的检测

2025-07-250
OAAI
Comparison of two methods for the estimation of COVID-19 vaccine effectiveness of the autumnal booster within the VEBIS-EHR network in 2022/23

2022/23年度在VEBIS-EHR网络中针对秋季加强针的两种COVID-19疫苗有效性估计方法的比较

2025-03-172
OAAI
Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study
2024-11-251
OA
Autochthonous dengue outbreak in Marche Region, Central Italy, August to October 2024
2024-11-210
OAAI
Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study
2024-09-018
PRE
Risk of breakthrough infection and hospitalisation after COVID-19 primary vaccination by HIV status in four Italian regions during 2021
2024-06-110
OAAI
Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study

10月2023年11月,XBB.1.5单价新型冠状病毒肺炎疫苗在欧盟/欧洲经济区国家XBB.1.5主导时期的有效性: vebis-ehr网络研究

2024-04-233
OA
Socioeconomic Inequalities in SARS-CoV-2 Infection and COVID-19 Health Outcomes in Urban Italy During the COVID-19 Vaccine Rollout, January-November 2021

2021年1月到11月新型冠状病毒肺炎疫苗推广期间意大利城市SARS-CoV-2感染和新型冠状病毒肺炎健康结果的社会经济不平等

2024-03-181
OAAI
Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study
2023-12-0123
OAAI
Estimating SARS-CoV-2 infections and associated changes in COVID-19 severity and fatality

估计SARS-CoV-2感染以及新型冠状病毒肺炎严重程度和死亡率的相关变化

2023-08-1614
OA
Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023
2023-08-1013
OAAI
Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022
2023-02-2316
OAAI